Article History
Received: 15 December 2022
Revised: 15 December 2022
Accepted: 6 January 2023
First Online: 13 January 2023
Declarations
:
: N.E.L. consults and is on an advisory board for United States Drug Testing Laboratories. A.D. has received personal consultancy fees from Roche, Incyte, Loxo Oncology and EUSA Pharma and research support from Roche and Takeda. The remaining author declares no competing financial interests related to this work.